Granules India's share price increased to Rs. 596.95, gaining 3.70 points or 0.62% compared to its previous close of Rs. 593.25 on the BSE.

The stock opened at Rs. 591.20, reaching a high of Rs. 601.50 and a low of Rs. 578.85 during the session, with 34,024 shares being traded.

The stock, classified in the BSE 'A' group with a face value of Rs. 1, has seen a 52-week high of Rs. 724.55 on September 2, 2024, and a 52-week low of Rs. 319.20 on October 26, 2023. In the past week, the stock hit a high of Rs. 613.45 and a low of Rs. 578.85. The company's current market capitalization stands at Rs. 14,464.56 crore.

Promoters hold 38.87% of the company's shares, with institutional investors and non-institutional investors holding 34.34% and 26.80%, respectively.

Granules India has received approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) in 100 mg, 150 mg, and 200 mg dosages. This approval, filed by Granules Pharmaceuticals, Inc., a wholly-owned subsidiary, signifies that the tablets are bioequivalent and therapeutically equivalent to Wellbutrin SR Sustained-Release Tablets by GlaxoSmithKline LLC. The medication is commonly prescribed for treating major depressive disorder and preventing seasonal affective disorder. With this latest approval, Granules India now has a total of 67 ANDA approvals from the USFDA.

Granules India is known for manufacturing and supplying pharmaceutical products, including active pharmaceutical ingredients (API), finished dosages (FDs), and formulation intermediates (PFI).